MiMedx Planning U.S. Launch for Ambient Temperature Version of OrthoFlo

MiMedx is planning a U.S. launch for a next-generation lyophilized (freeze-dried) version of OrthoFlo, its amniotic fluid-based allograft for use in in orthopaedic and sports-medicine applications.

This anticipated version of OrthoFlo can be stored at ambient temperature and has a...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0